IL-1 RAcP 詳細
Molecule Name
Interleukin-1 receptor accessory protein
分子の別称
IL1RAP,IL-1RAcP,C3orf13,IL1R3
Drug Development Progress
治験薬の数8
市販薬剤の数0
研究＆開発段階Phase 2 Clinical
ターゲットの別称
Interleukin-1 receptor 3，IL-1RAcP，IL-1 receptor accessory protein，IL-1R-3，C3orf13，Interleukin 1 Receptor Accessory Protein，IL1R3，Interleukin-1 Receptor Accessory Protein Beta，IL-1R3
バックグランド
Interleukin-1 receptor accessory protein (IL1RAP or IL-1RAcP) is also known as Interleukin-1 receptor 3 (IL-1R-3 or IL-1R3), C3orf13, which belongs to the interleukin-1 receptor family. IL1RAP contains three Ig-like C2-type (immunoglobulin-like) domains and one TIR domain. IL1RAP is detected in liver, skin, placenta, thymus and lung. IL-1R3 / IL1RAP is coreceptor with IL1R1, associates with IL1R1 bound to IL1B to form the high affinity interleukin-1 receptor complex which mediates interleukin-1-dependent activation of NF-kappa-B and other pathways.
IL-1 RAcP 製品リスト
You Have Viewed 0 Of 0 Results
治験薬に関する情報
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| Nidanilimab | CAN-04 | Phase 2 Clinical | Lund University Foundation | Biliary Tract Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Transitional Cell; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Melanoma; Myelodysplastic Syndromes; Pancreatic Neoplasms; Sarcoidosis, Pulmonary; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | 詳細 |
| CCTx-001 | CCTx-001 | Phase 2 Clinical | Advesya SAS | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 詳細 |
| SAR-445399 | SAR-445399 | Phase 2 Clinical | Sanofi | Hidradenitis Suppurativa; Immune System Diseases; Inflammation | 詳細 |
| IBI-3011 | IBI-3011; IBI3011 | Phase 1 Clinical | Arthritis, Gouty; Gout | 詳細 | |
| Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells therapy(Shanghai Zhongshan Hospital) | Phase 1 Clinical | Shanghai Zhongshan Hospital | Carcinoma, Hepatocellular | 詳細 | |
| AK-135 | AK135; AK-135 | Phase 1 Clinical | Peripheral Nervous System Diseases | 詳細 | |
| DXP-106 | DXP-106; DXP106 | Phase 1 Clinical | Singlomics Biopharmaceuticals Co Ltd | Neoplasms; Solid tumours | 詳細 |
| GSK-3903371 | GSK-3903371; BOS-371 | Clinical | Glaxosmithkline Plc | Neoplasms | 詳細 |